The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Abstract
Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease progression during or after platinum-based chemotherapy. Phase 1 data showed the safety and antitumor activity of amivantamab plus carboplatin–pemetrexed (chemotherapy). Additional data on this combination therapy are needed. Download a PDF of the Research Summary. In this phase 3, international, randomized trial, we assigned in a 1:1 ratio patients with advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy to receive intravenous amivantamab plus chemotherapy (amivantamab–chemotherapy) or chemotherapy alone. The primary outcome was progression-free survival according to blinded independent central review. Patients in the chemotherapy group who had disease progression were allowed to cross over to receive amivantamab monotherapy. A total of 308 patients underwent randomization (153 to receive amivantamab–chemotherapy and 155 to receive chemotherapy alone). Progression-free survival was significantly longer in the amivantamab–chemotherapy group than in the chemotherapy group (median, 11.4 months and 6.7 months, respectively; hazard ratio for disease progression or death, 0.40; 95% confidence interval [CI], 0.30 to 0.53; P<0.001). At 18 months, progression-free survival was reported in 31% of the patients in the amivantamab–chemotherapy group and in 3% in the chemotherapy group; a complete or partial response at data cutoff was reported in 73% and 47%, respectively (rate ratio, 1.50; 95% CI, 1.32 to 1.68; P<0.001). In the interim overall survival analysis (33% maturity), the hazard ratio for death for amivantamab–chemotherapy as compared with chemotherapy was 0.67 (95% CI, 0.42 to 1.09; P=0.11). The predominant adverse events associated with amivantamab–chemotherapy were reversible hematologic and EGFR-related toxic effects; 7% of patients discontinued amivantamab owing to adverse reactions. The use of amivantamab–chemotherapy resulted in superior efficacy as compared with chemotherapy alone as first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertions. (Funded by Janssen Research and Development; PAPILLON ClinicalTrials.gov number, NCT04538664.) QUICK TAKE VIDEO SUMMARYCombination Therapy in NSCLC with EGFR Exon 20 Insertions 02:15
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Self-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 655
Self-citationArcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 370
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0116 · Cited by 297
Self-citationMoores, S. L., Chiu, M. L., Bushey, B. S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R. J., Haytko, P., Kelly, T., Wu, S.-J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2833 · Cited by 286
Riess, J. W., Gandara, D. R., Frampton, G. M., Madison, R., Peled, N., Bufill, J. A., Dy, G. K., Ou, S.-H. I., Stephens, P. J., McPherson, J. D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.019 · Cited by 240
Vijayaraghavan, S., Lipfert, L., Chevalier, K., Bushey, B. S., Henley, B., Lenhart, R., Sendecki, J., Beqiri, M., Millar, H. J., Packman, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0071 · Cited by 206
Cho, B. C., Simi, A. K., Sabari, J. K., Vijayaraghavan, S., Moores, S. L., & Spira, A. I. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.11.004 · Cited by 148
Self-citationChemotherapy-induced thrombocytopenia: literature review
Gao, A., Zhang, L., & Zhong, D. (2023) · Discover Oncology · doi:10.1007/s12672-023-00616-3 · Cited by 100
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges
Ba, Y., Shi, Y., Jiang, W., Feng, J., Cheng, Y., Xiao, L., Zhang, Q., Qiu, W., Xu, B., Xu, R., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0069 · Cited by 97
Self-citationBurnett, H. F., Emich, H., Carroll, C., Stapleton, N., Mahadevia, P. J., & Li, T. M. W. Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247620 · Cited by 97
Bazhenova, L. A., Minchom, A. R., Viteri, S., Bauml, J. M., Ou, S. I., Gadgeel, S. M., Trigo, J. M., Backenroth, D., Li, T. M. W. Y., Londhe, A., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.020 · Cited by 91
Self-citationHou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., Zhou, H., Zhang, Z., Han, J., Wang, L., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00372-6 · Cited by 64
Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
Ou, S. I., Lin, H. M., Hong, J., Yin, Y., Jin, S., Lin, J., Mehta, M., Nguyen, D., & Neal, J. W. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100558 · Cited by 58
Viteri, S., Minchom, A. R., Bazhenova, L. A., Ou, S. I., Bauml, J. M., Shell, S. A., Schäffer, M., Gu, J., Rose, J. B., Curtin, J. C., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13327 · Cited by 44
Self-citationSanden, S. V., Murton, M., Bobrowska, A., Rahhali, N., Sermon, J., Rodrigues, B., Goff-Leggett, D., CHOUAID, C., Sebastian, M., & Greystoke, A. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00868-z · Cited by 39
Minchom, A. R., Viteri, S., Bazhenova, L. A., Gadgeel, S. M., Ou, S. I., Trigo, J. M., Bauml, J. M., Backenroth, D., Bhattacharya, A., Li, T. M. W. Y., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.005 · Cited by 37
Self-citationGirard, N., Minchom, A. R., Ou, S. I., Gadgeel, S. M., Trigo, J. M., Viteri, S., Bauml, J. M., Londhe, A., Mahadevia, P. J., & Bazhenova, L. A. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.007 · Cited by 22
Self-citationCHOUAID, C., Bosquet, L., Girard, N., Kron, A., Scheffler, M., Griesinger, F., Sebastian, M., Trigo, J. M., Arias, C. S. V., Knott, C. S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02408-7 · Cited by 18
Self-citationAgrawal, T., Artis, E., Xie, J., Bhattacharya, A., Haddish‐Berhane, N., Gopen, T., Curtin, J. C., Karkera, J. D., Roshak, A., Knoblauch, R. E., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1131 · Cited by 14
Self-citation
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J.-S., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., Liu, B., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403614 · Cited by 458
Self-citationNew promises and challenges in the treatment of advanced non-small-cell lung cancer
Meyer, M.-L., Fitzgerald, B. G., Paz-Ares, L., Cappuzzo, F., Jänne, P. A., Peters, S., & Hirsch, F. R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01029-8 · Cited by 453
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 415
Metadata
- Authors
- Zhou, C., Tang, K.-J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J. W., Sabari, J. K., Sanborn, R. E., Mansfield, A. S., Hung, J.-Y., Boyer, M., Popat, S., Mourão Dias, J., Felip, E., Majem, M., Gumus, M., Kim, S.-W., Ono, A., Xie, J., Bhattacharya, A., Agrawal, T., Shreeve, S. M., Knoblauch, R. E., Park, K., & Girard, N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-11-30
- Volume
- 389
- Issue
- 22
- Pages
- 2039-2051
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387844767
- Cited by
- 381
- References
- 26
- FWCI
- 60.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.